Recent Updates
Recently added Catalysts

endovenous ablation+polidocanol injectable microfoam 0.125%

Phase 3

Great Saphenous Vein Incompetence | Small molecule | Cardiovascular |Boston Scientific Corporation|Last Updated: Apr 21, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment117

FDA Designations

No designations recorded

Clinical trial landscape

endovenous ablation+polidocanol injectable microfoam 0.125% · 1 trial · 2 indications

Phase 3 1
NCT01197833Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible VaricositiesGreat Saphenous Vein Incompetence
COMPLETED117 Analytics
PHASE3COMPLETED
Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities
Great Saphenous Vein IncompetenceUnlock trial analytics

Study Endpoints

Primary Endpoints

Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score)
IPR-V3 measured at baseline and then at 8 weeks

The Independent Photography Review - Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At screening, the site clinician was instructed to review the appearance of the patient's varicose veins in the medial section of each leg (a 'live' assessment), then select an IPR-V3 score (i.e., none=0, mild, moderate, severe or very severe=4) that best represented the appearance of the patient's varicose veins. This assessment took into account the attributes caliber, dilatation, tortuosity, and extent and number of varicosities, and was used to determine patient eligibility. The site clinician used a set of reference photographs (2 example photographs for each score on the scale) to assist with assigning a score to the appearance of the patient's visible varicose veins.

Absolute Change From Baseline in PA-V3 Score
PA-V3 measured at baseline and then at 8 weeks

The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from "Not at all noticeable" (a score of 0) to "Extremely noticeable" (a score of 4)

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Endovenous ablation+polidocanol injectable microfoam 0.125%EXPERIMENTALEndovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
Endovenous ablation+polidocanol injectable micrfoam, 1.0%EXPERIMENTALEndovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
endovenous ablation+vehicle (placebo)ACTIVE_COMPARATORendovenous ablation followed by injection of vehicle (placebo) to target vein

Interventions

NameTypeDescription
endovenous ablation+polidocanol injectable microfoam 0.125%DRUGAll components except API
Endovenous ablation+polidocanol injectable microfoam 1.0%DRUGendovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
Endovenous ablation+polidocanol injectable foam 2.0%DRUGEndovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites7

Inclusion Criteria: * Incompetence of SFJ * Patients who are candidates for ETA \[laser or radiofrequency ablation (RFA)\] * Symptomatic varicose veins * Visible varicose veins * Ability to comprehend and sign an informed consent and complete study questionnaires in English Exclusion Criteria: * ...

Countries:United States
Unlock Eligibility Criteria